All In MedTech

Device Trial Radar · NCT05612854

Catheter Directed Therapy in Intermediate Risk Pulmonary Embolism Patients

Catheter Directed Therapy for Intermediate Risk Pulmonary Embolism Patients Guided by Prediction Model for Impending Shock

Last checked: Nov 20, 2026Latest source record: Nov 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 30, 2022

Primary completion

Dec 30, 2023

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Assiut UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 10, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aim of the work: 1. To compare conventional medical therapy versus catheter-directed therapy in intermediate high risk acute pulmonary embolism. 2. To define predictors of progression from intermediate to high-risk in medically-treated patients for ideal timing for intervention.

Conditions

  • Pulmonary Embolism Subacute Massive

Interventions

  • Mechanical embolectomy: by hydromechanical defragmentation by pigtailProcedure

    Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation

  • Suction embolectomy by the Penumbra Indigo aspiration systemDevice

    The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries. 510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1.comparison between conventional medical therapy and catheter-directed therapy in intermediate high risk acute pulmonary embolism patientsTime frame: up to 2 years

2 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.